NEW_CURA-LEAF_1170x120_OCT

Biosimilars Forum

Physicians exhibit knowledge gap with biosimilars

Physicians exhibit knowledge gap with biosimilars

WASHINGTON — Though the vast majority of specialty physicians know what biosimilars are, their knowledge about these emerging medications falls short, according to a survey by the Biosimilars Forum. Of 1,201 U.S. physicians polled, 76.8% had heard the term biosimilars within the previous month, the Biosimilars Forum said Tuesday. Yet respondents exhibited five key gaps

FDA proposes suffix for biosimilar product names

FDA proposes suffix for biosimilar product names

WASHINGTON — Early feedback on the Food and Drug Administration’s proposal on naming conventions for biosimilars shows a mixed response. Late late week, the FDA published draft guidance recommending that reference biologic products and biosimilars have nonproprietary names that share a core drug substance name and an FDA-designated suffix unique for each product. For interchangeable

Pharmaceutical companies form Biosimilars Forum

WASHINGTON — A coalition of 11 biopharmaceutical companies has formed the Biosimilars Forum, described as the first nonprofit organization for expanding patient access to biosimilars in the United States. The group said Tuesday that its founding members represent the majority of companies with the most significant U.S. biosimilars development portfolios, including Actavis, Amgen, Boehringer Ingelheim,